EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Machine Learning-Guided Prediction of Formulation Performance in Inhalable Ciprofloxacin–Bile Acid Dispersions with Antimicrobial and Toxicity Evaluation

Tareq Zeyad Bahjat, Twana Mohammed M Ways, Sadat Abdulla Aziz, Aram Ismael Ibrahim, Deon Danto, Veneece Ghattas, Goran Mohammed Raouf, Glyn Barrett iD, Dana Khdr Sabir, Pyman Mohamed Mohamedsalih, Hisham Al-Obaidi iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.5c00663 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Tareq Zeyad Bahjat und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Reading, Reading RG6 6AD, U.K. Hauptthemen laut MEDLINE: Ciprofloxacin, Machine Learning, Anti-Bacterial Agents, Bile Acids and Salts. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ciprofloxacin (CFX) is a potent antibiotic for respiratory infections, but its poor solubility and high crystallinity limit its effectiveness in dry powder inhaler (DPI) delivery. Although soluble forms such as CFX hydrochloride are available, their rapid dissolution may lead to systemic absorption, undermining localized lung targeting. To address this, we developed solid dispersions of CFX with primary bile acids, namely, cholic acid (CA) and chenodeoxycholic acid (CDA), using spray drying and ball milling to enhance solubility in a controlled manner while maintaining deposition in the lungs. Differential scanning calorimetry showed glass-transition temperature (Tg) values were elevated for both bile acids, with CA dispersions showing slightly higher absolute values (114.16-131.77 °C vs 109.13-120.67 °C). However, Fourier transform infrared and dissolution data indicated that CDA formed stronger directional hydrogen bonding with CFX. X-ray diffraction confirmed partially amorphous dispersions with minimal residual crystallinity. Solubility enhancement was observed for both bile acids, showing slightly higher values with CA dispersions. Aerodynamic assessments using an Andersen cascade impactor revealed improved lung deposition with CFX-CDA, with a higher fine particle fraction (FPF: 30.81%) and lower mass median aerodynamic diameter (MMAD: 5.89 μm) compared to CFX-CA (FPF: 26.93%, MMAD: 6.19 μm). The emitted dose was highest in CDA with nearly 5 mg compared to CA dispersions (∼3 mg). In vitro antimicrobial studies showed that dispersions maintained comparable antimicrobial activity to pure CFX, while in vivo toxicology in rats indicated mild, dose-dependent hepatic changes. CDA formulations showed AST elevation at a low dose and ALP increase at a high dose, consistent with the known hepatic effects of this bile acid, while CA formulations were broadly comparable to pure CFX. Machine learning algorithms, including tree-based models and neural networks, were used to predict the formulation performance and identify critical variables. Feature selection was achieved using recursive elimination, and permutation analysis showed that the bile acid type, inlet temperature, and molar ratio were the most influential predictors of solubility and lung deposition. Models such as gradient boosting and elastic net showed a high predictive accuracy (R2 > 0.85). Overall, this study highlights the potential of primary bile acid-based DPI formulations as effective inhalable antibiotic therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CiprofloxacinMachine LearningAnti-Bacterial AgentsBile Acids and SaltsAnimalsRatsSolubilityAdministration, InhalationDry Powder InhalersMaleChenodeoxycholic AcidCholic AcidRats, Sprague-DawleyChemistry, PharmaceuticalDrug CompoundingLungX-Ray DiffractionCalorimetry, Differential ScanningSpectroscopy, Fourier Transform Infrared

Stichwörter der Autor:innen

antimicrobial activitybile acidsciprofloxacindry powder inhaler (DPI)lung depositionmachine learningsolid dispersionsspray drying

Substanzen

CiprofloxacinAnti-Bacterial AgentsBile Acids and SaltsChenodeoxycholic AcidCholic Acid

Autor:innen und Institutionen

  • School of Pharmacy, University of Reading, Reading RG6 6AD, U.K.
  • Department of Pharmaceutics, College of Pharmacy, University of Sulaimani, Sulaymaniyah, Kurdistan Region 46001, Iraq.
  • Department of Anaesthesia, College of Health Sciences, Cihan University-Sulaimaniya, Sulaymaniyah, Kurdistan Region 46001, Iraq.
  • Department of Basic Sciences, College of Vet. Medicine, University of Sulaimani, Sulaymaniyah, Kurdistan Region 46001, Iraq.
  • Basic Medical Sciences, College of Medicine, University of Sulaimani, Sulaymaniyah, Kurdistan Region 46001, Iraq.
  • School of Biological Sciences, University of Reading, Reading RG6 6AD, U.K.

ORCID-Profile: Glyn Barrett, Hisham Al-Obaidi

Zitieren

APA

Bahjat, T. Z., Mohammed M Ways, T., Aziz, S. A., Ibrahim, A. I., Danto, D., Ghattas, V., Raouf, G. M., Barrett, G., Sabir, D. K., Mohamedsalih, P. M., & Al-Obaidi, H. (2025). Machine Learning-Guided Prediction of Formulation Performance in Inhalable Ciprofloxacin–Bile Acid Dispersions with Antimicrobial and Toxicity Evaluation. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00663

Vancouver

Bahjat TZ, Mohammed M Ways T, Aziz SA, Ibrahim AI, Danto D, Ghattas V, et al. Machine Learning-Guided Prediction of Formulation Performance in Inhalable Ciprofloxacin–Bile Acid Dispersions with Antimicrobial and Toxicity Evaluation. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00663

BibTeX
@article{Bahjat2025,
  author = {Bahjat, Tareq Zeyad and Mohammed M Ways, Twana and Aziz, Sadat Abdulla and Ibrahim, Aram Ismael and Danto, Deon and Ghattas, Veneece and Raouf, Goran Mohammed and Barrett, Glyn and Sabir, Dana Khdr and Mohamedsalih, Pyman Mohamed and Al-Obaidi, Hisham},
  title = {Machine Learning-Guided Prediction of Formulation Performance in Inhalable Ciprofloxacin–Bile Acid Dispersions with Antimicrobial and Toxicity Evaluation},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.5c00663}
}
Kostenlos starten →